top of page
Search

September 14 is an FDA hearing — not a CSA reschedule

Thynk Industries
Sep 9
4 min read

Trade headlines will treat Monday like a scheduling vote. The Federal Register does not.

On September 14, 2026, from 12:30 p.m. to 4:30 p.m. ET, FDA holds a hybrid 21 CFR part 15 public hearing on considerations for the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings. Primary: FR Doc 2026-14155, 91 FR 43095–43098 (GovInfo HTML). Docket FDA-2026-N-7542. Meeting page: FDA hearing 09/14/2026. Written comments stay open through October 5, 2026 on regulations.gov. Requests to present closed August 21.

A part 15 hearing is process. It is not a Controlled Substances Act scheduling order.

What FDA said it will not take comment on

The same notice draws a bright line. FDA is not seeking comment on:

  1. Safety or effectiveness of any particular drug product, or the merits of any pending application

  2. The scheduling status of any substance under the Controlled Substances Act, which is addressed through separate statutory processes

  3. Legalization or decriminalization of psychedelic substances, or the merits of state or local programs (FDA does welcome data-collection input from those programs)

  4. Religious, ceremonial, or personal non-medical use

  5. Individual disputes or enforcement complaints against specific practitioners

That list is the story. If Monday's coverage collapses "FDA psychedelics hearing" into "DEA is about to reschedule psilocybin," the primary text already refused that frame.

What the hearing is about

FDA and federal partners asked for input on four operational buckets: provider training and credentialing, patient safety (set/setting, informed consent, screening, diversion controls), access (coverage, workforce, clinic capacity, telehealth coordination), and data collection / standardization (registries, common data elements, adverse-event definitions). Those are supervised-setting build questions for a future approved product pathway — not a leaf-market free-for-all.

Same July 14 Federal Register day also finalized industry guidance: FR Doc 2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations. Guidance for sponsors designing trials is not a marketing approval and not a schedule change.

Three clocks. Do not share one headline.

Clock / document

What it is

Status

FDA FR 2026-14155

Part 15 hearing on supervised therapeutic use

Sep 14, 2026 hearing; comments through Oct 5

FDA FR 2026-14158

Final clinical-investigations guidance

Live since Jul 14, 2026

CSA scheduling

Separate DEA / HHS statutory process

Out of scope for this hearing

HHS FR 2026-17409

7-OH threshold RFI comment extension

Closed Sep 10, 2026 — different industry

DEA FR 2026-17429

Temp Schedule I for MP / MGM-15 / MGM-16

Live since Aug 26

P.L. 119-103 hemp clocks

Nov 12 non-naturally-producible; Dec 11 most remaining §781

Separate rail — already covered on thynk.guru

Kratom / 7-OH operators already have the September 10 comment-window analysis live at september-10-closes-a-comment-window-not-a-schedule-i-order. Hemp operators still run a signed split clock under P.L. 119-103 (Became Public Law 09/02/2026), covered at signed-split-clock-nov-12-and-dec-11. Psychedelic operators watching Monday's hearing should not borrow either headline.

Texas DSHS Schedule I for manufactured non-Δ9 isomers remains in force on the hemp/isomer side. One lock line; do not reopen Texas here.

Microregulator prediction

After September 14, expect clips that say "FDA moves on psychedelics." Watch for three different things: (1) the hearing transcript and docket comments (process), (2) any later NDA / marketing action on a specific product (approval), (3) a separate DEA temporary or permanent scheduling document in the Federal Register (CSA). Only (3) changes the Controlled Substances Act table. Oregon and Colorado state-regulated service programs remain state law until a federal schedule or product approval says otherwise — and this hearing expressly declined to adjudicate those programs' merits.

Personal thoughts

Operators keep buying one Monday for three statutes. September 10 closed a comment window on a 7-OH threshold — already live at https://www.thynk.guru/post/september-10-closes-a-comment-window-not-a-schedule-i-order. September 14 is a part 15 hearing on supervised therapeutic use. Neither is a CSA rewrite. If you run a supervised-setting program, use the docket topics (training, safety, access, data) as your compliance map — not Discord. If you also sell hemp or kratom SKUs, keep those rails dual-mapped against P.L. 119-103 and FR 2026-17429 on https://thynkflow.io, not against an FDA hearing agenda.

Supervised-setting licensing and multi-rail consulting: https://www.thynk.guru/contact-us. Catalog dual-map when hemp / kratom / synthetics share a shelf: https://thynkflow.io.

Disclaimer. This article is operator analysis from Thynk Industries, not legal advice, not a lobbying communication, and not a prediction sold as a later statute. A part 15 hearing notice, a guidance document, a trade blog, a language model, and a "FDA is rescheduling Monday" rumor are not substitutes for counsel reading FR 2026-14155, FR 2026-14158, your state program rules, any later Federal Register scheduling order, and any FDA approval that actually issues.

Sources (primary / documented first)

  1. FDA, FR Doc 2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments (91 FR 43095–43098; hearing Sep 14, 2026; comments through Oct 5, 2026; Docket FDA-2026-N-7542). https://www.federalregister.gov/documents/2026/07/14/2026-14155/considerations-for-potential-future-therapeutic-use-of-psychedelic-drugs-public-hearing-request-for

  2. GovInfo HTML, FR 2026-14155. https://www.govinfo.gov/content/pkg/FR-2026-07-14/html/2026-14155.htm

  3. FDA meeting page — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing (09/14/2026). https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026

  4. FDA, FR Doc 2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability. https://www.federalregister.gov/documents/2026/07/14/2026-14158/psychedelic-drugs-considerations-for-clinical-investigations-guidance-for-industry-availability

  5. H.R. 6500 / P.L. 119-103 (Became Public Law 09/02/2026) — hemp split-clock context only. https://www.congress.gov/bill/119th-congress/house-bill/6500

  6. HHS OASH, FR Doc 2026-17409 — 7-OH threshold RFI comments through Sep 10, 2026 (adjacent clock, not this hearing). https://www.federalregister.gov/documents/2026/08/26/2026-17409/hydroxymitragynine-above-a-specified-threshold-in-schedule-i-extension-of-comment-period

  7. DEA, FR Doc 2026-17429 — temporary Schedule I for MP, MGM-15, MGM-16 (adjacent, not this hearing). https://www.federalregister.gov/documents/2026/08/26/2026-17429/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and

 
 
 

Comments

bottom of page